Drug
Cr845
Cr845: highest development phase Phase 3, developed by Cara Therapeutics. 8 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Cara Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| CR845 NCT03281538 | Phase 3 | Uremic Pruritus |
| CR845 NCT01789476 | Phase 2 | Acute Pain |
| CR845 NCT01361568 | Phase 2 | Postoperative Pain |
| CR845 0.25 mg NCT02524197 | Phase 2 | Osteoarthritis |
| CR845 0.25 mg Oral Tablet NCT03617536 | Phase 2 | Chronic Kidney Diseases |
| CR845 tablet 1 mg NCT02944448 | Phase 2 | Osteoarthritis, Hip |
| CR845 1.0 mg NCT03995212 | Phase 2 | Cholestatic Pruritus |
| CR845 NCT00877799 | Phase 2 | Acute Pain |
Latest
No recent events.
Follow Cr845 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.